<DOC>
	<DOCNO>NCT02486302</DOCNO>
	<brief_summary>The purpose non-interventional study evaluate efficacy etanercept routine clinical use maximum 12 month patient rheumatoid arthritis , psoriatic arthritis , axial spondyloarthritis , plaque psoriasis . In , particular attention pay proportion patient attain desired treatment goal 12 week treatment . The primary efficacy end point study proportion patient attain desired treatment goal 12 24 week ,</brief_summary>
	<brief_title>A Study To Evaluate The Efficacy Of Enbrel ( REGISTERED ) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis , Axial Spondyloarthritis , Psoriatic Arthritis , Or Plaque Psoriasis .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Confirmed diagnosis RA , axSpA , PsA PsO No prior treatment etanercept eligibility treatment etanercept accord summary product characteristic . The contraindication , special warning , precaution accord summary product characteristic etanercept shall apply . The additional documentation patient another postmarketing study etanercept permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>